Table 1.

Summary of viloxazine and methylphenidate plasma pharmacokinetic parameters

Parameter	Viloxazine plasma pharmacokinetics		Parameter	Methylphenidate plasma pharmacokinetics
	Viloxazine ER alone [n = 34]	Combination [n = 34]		Methylphenidate alone [n = 34]	Combination [n = 34]
Cmax, µg/mL	4.73 ± 0.86	4.84 ± 0.89	Cmax, ng/mL	10.8 ± 5.00	11.1 ± 4.44
AUCt, h·µg/mL	101.7 ± 20.57	102.2 ± 20.13	AUCt, h·ng/mL	128.1 ± 75.12	134.8 ± 65.10
AUC∞, h·µg/mL	102.6 ± 20.73	103.4 ± 20.36	AUC∞, h·ng/mL	128.7 ± 75.29	135.3 ± 65.17
Tmax, h	5.0 (3.0–10.0)	5.0 (4.0–10.0)	Tmax, h	6.0 (1.0–10.0)	6.0 (1.0–12.0)
λz, 1/h	0.13 ± 0.05	0.12 ± 0.04	λz, 1/h	0.17 ± 0.03	0.17 ± 0.03
t½, h	6.30 ± 2.53	6.81 ± 2.39	t½, h	4.37 ± 0.93	4.26 ± 0.90
CL/F, mL/min	119 ± 28.7	118 ± 28.2	CL/F, mL/min	5530 ± 2030	5140 ± 1770
Vd/F, L	63.4 ± 26.6	67.6 ± 22.7	Vd/F, L	2000 ± 655	1810 ± 513

Data are expressed as mean ± SD except for T_max, which is expressed as median (range)

AUC_t area under the concentration–time curve from time zero to the last measurable time, AUC_∞ area under the concentration–time curve from time 0 to infinity; CL/F apparent total clearance of drug, C_max maximum measured plasma concentration, ER extended-release, λ_z terminal elimination rate constant, SD standard deviation, t_½ terminal elimination half-life, T_max time of the maximum measured plasma concentration, V_d/F apparent volume of distribution